The Centers for Disease Control and Prevention (CDC) said in an update yesterday that it has concluded its investigation into a 10-state outbreak of Escherichia coli linked to contaminated clover sprouts that sickened 51 people, up 12 from the agency's Mar 19 update.
Three more Ebola cases have been confirmed in the Democratic Republic of the Congo (DRC), raising the outbreak total to 3,354 cases, according to numbers reflected on the World Health Organization (WHO) online Ebola dashboard.
Health officials are still investigating 488 suspected cases. Also, 3 more people died from their infections, lifting the fatality count to 2,220.
The Democratic Republic of the Congo's (DRC's) Ebola technical committee said there are three new cases of Ebola today, raising the outbreak total to 3,343, and 432 suspected cases are under investigation.
The technical committee, the CMRE, said the death toll now stands at 2,210. Today's cases come from Mabalako and Biena, which had gone 85 days without a new case.
The vaccine produced a strong immune response and fewer lesions than ACAM2000.
Takeda's dengue vaccine candidate (TAK-003) is safe and effective against dengue virus, according to part 1 of phase 3 clinical trial results published yesterday in the New England Journal of Medicine.
In its weekly flu update today, the US Centers for Disease Control and Prevention (CDC) reported the first pediatric flu deaths of the new season and noted that the nation's flu activity increased slightly last week but is still at low levels.
In one key category, under 7% of countries scored in the highest tier.
The Global Polio Eradication Initiative (GPEI) in its latest weekly update today noted new cases of polio in Pakistan, Angola, and Myanmar—all countries battling ongoing outbreaks of wild or vaccine-derived poliovirus.
The US Centers for Disease Control and Prevention (CDC) announced yesterday that the Pan American Health Organization (PAHO)/World Health Organization (WHO) have designated the CDC's Center for Global Health as a PAHO/WHO Collaborating Center for Biosafety and Biosecurity.
Genentech, part of the Roche Group, yesterday announced promising phase 3 trial findings for the use of one-dose baloxavir marboxil (Xofluza) to safely treat flu in children, according to results presented on Sep 1 during the Options X Congress in Singapore.
